US Sets Zero Tariff on Certain Specialty Drugs from India
Indiadailyupdate.com – The US sets zero tariff on certain specialty medicines and pharmaceutical ingredients imported from India and 19 other countries. The exemption applies to qualifying products used in advanced treatments, while separate duties remain in place for specified patented pharmaceutical imports.
India is among 20 countries and jurisdictions eligible for the zero per cent ad valorem tariff rate. This means qualifying imports will not face a customs duty calculated as a percentage of their declared value.
Which medicines and ingredients qualify?
The zero-tariff provision covers products linked to rare diseases, infertility treatment, cell therapies, gene therapies, antibody-drug conjugates and animal pharmaceuticals. Components and ingredients used to manufacture these products can also qualify, subject to US Commerce Department conditions.
The decision is important for specialised medicines that depend on global supply chains. Cell and gene therapies, for example, often require complex biological materials and tightly controlled manufacturing processes. Relief for ingredients may help support the supply of these advanced treatments.
The US sets zero tariff on certain products under a narrower exemption within its wider pharmaceutical import programme. The measure does not provide blanket tariff relief for all medicines shipped from India or other eligible countries.
How the wider US pharmaceutical tariff plan applies
The exemption is part of the implementation of an April proclamation on pharmaceutical imports and pharmaceutical ingredients under Section 232 of the Trade Expansion Act. The administration has said the broader action is intended to encourage pharmaceutical manufacturing in the United States.
Specified patented drugs, biologics and related ingredients are subject to a 100 per cent tariff under the wider plan. One phase took effect on July 31 for companies named in an annex, while another stage is due to cover additional companies from September 29.
Generic medicines and their related ingredients are not included in the Section 232 pharmaceutical tariff regime. This distinction matters because generics form a substantial part of routine medicine supply and have a different regulatory and commercial status from patented products.
Countries covered by the exemption
Besides India, the eligible countries and jurisdictions are Argentina, Bangladesh, Cambodia, Ecuador, El Salvador, the European Union, Guatemala, Indonesia, Japan, Jordan, Malaysia, North Macedonia, South Korea, Switzerland, Liechtenstein, Taiwan, Thailand, the United Kingdom and Vietnam.
Eligibility is connected to an existing or anticipated trade and security framework agreement with Washington. The Commerce Department identified the covered countries in a Federal Register notice issued during the rollout of the pharmaceutical import measures.
The notice also clarifies product definitions. It expressly includes unpatented animal health products within the meaning of generic pharmaceutical articles and limits “pharmaceutical articles” to finished products, active pharmaceutical ingredients and key starting materials.
What it means for Indian drug exporters
For Indian pharmaceutical manufacturers, the US sets zero tariff on certain qualifying specialty exports, potentially improving access to the American market for eligible products. Exporters must still verify both product classification and country-specific requirements before claiming the benefit.
The exemption may be especially relevant for businesses supplying specialised therapies, fertility medicines, veterinary products and pharmaceutical inputs. Goods outside the defined exemption, including covered patented products, may remain subject to US duties.
FAQ for Indian pharmaceutical exporters
Do all medicines exported from India receive zero tariff treatment?
No. The relief applies only to qualifying specialty medicines, animal pharmaceuticals, ingredients and components that meet the US conditions. It is not a universal exemption for all Indian pharmaceutical exports.
Are generic medicines covered by the 100 per cent tariff?
No. Generic medicines and related ingredients are outside the Section 232 pharmaceutical tariff regime described in the measure.
What should Indian exporters check before shipping?
Exporters should confirm the product’s tariff classification, whether it fits an eligible specialty category, and whether all Commerce Department requirements are met. They should also distinguish exempt products from patented goods that may still face tariffs.
